Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers [ChIP-Seq]
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 30 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Samples
- 30 samples: 15 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE285986_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1207211 and SRA study SRP555639. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 30 samples.
How we read this: 15 replicated groups read from 30 sample titles; they account for 30 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM8714523 Input_DMSO_Rep1 Input_DMSO
- GSM8714524 Input_DMSO_Rep2 Input_DMSO
- GSM8714525 Input_JIB04_150nM_Rep1 Input_JIB04_150nM
- GSM8714526 Input_JIB04_150nM_Rep2 Input_JIB04_150nM
- GSM8714527 Input_JIB04_500nM_Rep1 Input_JIB04_500nM
- GSM8714528 Input_JIB04_500nM_Rep2 Input_JIB04_500nM
- GSM8714529 H3K27ac_DMSO_Rep1 H3K27ac_DMSO
- GSM8714530 H3K27ac_DMSO_Rep2 H3K27ac_DMSO
- GSM8714531 H3K27ac_JIB04_150nM_Rep1 H3K27ac_JIB04_150nM
- GSM8714532 H3K27ac_JIB04_150nM_Rep2 H3K27ac_JIB04_150nM
- GSM8714533 H3K27ac_JIB04_500nM_Rep1 H3K27ac_JIB04_500nM
- GSM8714534 H3K27ac_JIB04_500nM_Rep2 H3K27ac_JIB04_500nM
- GSM8714535 H3K4me3_DMSO_Rep1 H3K4me3_DMSO
- GSM8714536 H3K4me3_DMSO_Rep2 H3K4me3_DMSO
- GSM8714537 H3K4me3_JIB04_150nM_Rep1 H3K4me3_JIB04_150nM
- GSM8714538 H3K4me3_JIB04_150nM_Rep2 H3K4me3_JIB04_150nM
- GSM8714539 H3K4me3_JIB04_500nM_Rep1 H3K4me3_JIB04_500nM
- GSM8714540 H3K4me3_JIB04_500nM_Rep2 H3K4me3_JIB04_500nM
- GSM8714541 H3K9me2_DMSO_Rep1 H3K9me2_DMSO
- GSM8714542 H3K9me2_DMSO_Rep2 H3K9me2_DMSO
- GSM8714543 H3K9me2_JIB04_150nM_Rep1 H3K9me2_JIB04_150nM
- GSM8714544 H3K9me2_JIB04_150nM_Rep2 H3K9me2_JIB04_150nM
- GSM8714545 H3K9me2_JIB04_500nM_Rep1 H3K9me2_JIB04_500nM
- GSM8714546 H3K9me2_JIB04_500nM_Rep2 H3K9me2_JIB04_500nM
- GSM8714547 H3K9me3_DMSO_Rep1 H3K9me3_DMSO
- GSM8714548 H3K9me3_DMSO_Rep2 H3K9me3_DMSO
- GSM8714549 H3K9me3_JIB04_150nM_Rep1 H3K9me3_JIB04_150nM
- GSM8714550 H3K9me3_JIB04_150nM_Rep2 H3K9me3_JIB04_150nM
- GSM8714551 H3K9me3_JIB04_500nM_Rep1 H3K9me3_JIB04_500nM
- GSM8714552 H3K9me3_JIB04_500nM_Rep2 H3K9me3_JIB04_500nM
- GSE289805 Histone H4 lysine 20 tri-methylation safeguards breast cancer lineage fidelity and unfolded protein response [ChIP-seq/ATAC-seq] 126 samples shares fidelity, chip-seq
- GSE236589 Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer [ChIP-Seq] 12 samples shares therapeutic, chip-seq
- GSE262797 A one-base therapeutic insertion in the HBG2 distal promoter reactivates γ-globin expression [ChIP-Seq] 10 samples shares therapeutic, chip-seq
- GSE295392 PIKfyve-regulated lipid metabolism as a therapeutic vulnerability in neuroendocrine prostate cancer 82 samples shares vulnerability, therapeutic
- GSE275637 ATF4-Mediated Metabolic Stress Response as a Therapeutic Vulnerability in Chordoma 50 samples shares vulnerability, therapeutic
- GSE276695 Chemotherapeutic agents and leucine deprivation induce codon-biased aberrant protein production in cancer 24 samples shares therapeutic, other
- GSE280973 Transcriptional Regulation of Protein Synthesis by Mediator Kinase Represents a Therapeutic Vulnerability in MYC-driven Medulloblastoma 20 samples shares vulnerability, therapeutic
- GSE241989 Immunotherapeutic targeting of surfaceome heterogeneity in AML 18 samples shares therapeutic, other
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.